Published Date: 02 Mar 2023
Multiple sclerosis patients who cut calories two days a week not only lost weight but also experienced better cognition and other benefits in a new study.
Read Full NewsAbdominal and chest pain. Injuries. Breathing difficulty. Infections. Mental health emergencies. Those are some of the most common reasons why people go to the local emergency department.
University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more difficult to detect than ...
Cancer treatment has come a long way, but many of today's therapies still come with steep costs: not just financial, but physical and emotional too. Chemotherapy and radiotherapy remain vital tools, yet they often damage ...
1.
Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.
2.
A Win for Molecularly Guided Therapy for Cancer of Unknown Primary
3.
Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds
4.
FDA Authorizes Three Different Uses for Injectable Antibiotic.
5.
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
1.
A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
The Benefits and Risks of Cervical Conization
4.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
5.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation